Stock listing
Frankfurt:87S Roivant Sciences Ltd. Aktie
German listing (Frankfurt) of Roivant Sciences Ltd. · home listing NASDAQ:ROIV
Follow Roivant Sciences Ltd. into a list and get an email when it puts out news.
Share price · FWB:87S
€34.64 EUR +0.07 (+0.2%)
Close on Nov 20, 2026
- Day range
- €34.64 – €35.11 EURNov 20, 2026
- Market cap
- €25.02B EURAt the close on Nov 20, 2026 · price × 722.3M shares outstanding
- 52-week range
- €16.73 – €35.90 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €7,107 EURMedian day 0 shares · 31 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ROIV · Home | $38.66 USD | -0.075 (-0.2%) | 3,969,952 | $38.86 | $39.51 | $38.46 | $38.73 | Close on Nov 20, 2026 |
| Frankfurt:87S | €34.64 EUR | +0.07 (+0.2%) | — | €35.02 | €35.11 | €34.64 | €34.57 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:87S · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €31.88 | -1.85 | -5.5% | €32.18 | €32.27 | €31.78 | 0 | |
| €33.73 | +1.90 | +6.0% | €33.78 | €33.81 | €33.50 | 1,400 | |
| €31.83 | +0.661 | +2.1% | €31.87 | €31.96 | €31.78 | 1,400 | |
| €31.16 | -1.604 | -4.9% | €31.17 | €31.17 | €31.16 | 360 | |
| €32.77 | -0.635 | -1.9% | €32.77 | €32.77 | €32.61 | 0 | |
| €33.40 | -0.305 | -0.9% | €33.42 | €33.42 | €32.91 | 60 | |
| €33.71 | +1.228 | +3.8% | €33.22 | €33.73 | €32.99 | 1,000 | |
| €32.48 | +0.317 | +1.0% | €32.00 | €32.67 | €31.91 | 1,000 | |
| €32.16 | -0.17 | -0.5% | €31.87 | €32.29 | €31.41 | 0 | |
| €32.33 | -0.418 | -1.3% | €32.43 | €32.51 | €32.00 | 0 | |
| €32.75 | +0.65 | +2.0% | €32.99 | €33.20 | €32.39 | 118 | |
| €32.10 | -0.203 | -0.6% | €32.27 | €32.49 | €32.02 | 120 | |
| €32.30 | +2.308 | +7.7% | €30.55 | €32.41 | €30.45 | 120 | |
| €30.00 | +0.401 | +1.4% | €30.54 | €30.55 | €29.81 | 0 | |
| €29.60 | -0.366 | -1.2% | €29.57 | €29.63 | €29.55 | 0 | |
| €29.96 | +0.342 | +1.2% | €30.11 | €30.11 | €29.89 | 0 | |
| €29.62 | +0.352 | +1.2% | €29.67 | €29.67 | €29.58 | 0 | |
| €29.27 | -1.703 | -5.5% | €29.42 | €29.73 | €29.26 | 0 | |
| €30.97 | +0.84 | +2.8% | €31.17 | €31.17 | €30.74 | 0 | |
| €30.13 | +0.084 | +0.3% | €31.16 | €31.27 | €29.81 | 0 | |
| €30.05 | -0.179 | -0.6% | €30.28 | €30.30 | €30.02 | 240 | |
| €30.23 | -0.907 | -2.9% | €30.40 | €30.63 | €30.21 | 240 | |
| €31.13 | -0.221 | -0.7% | €31.16 | €31.27 | €30.78 | 0 | |
| €31.35 | -0.143 | -0.5% | €31.52 | €31.58 | €31.05 | 600 | |
| €31.50 | +0.191 | +0.6% | €31.56 | €31.58 | €31.48 | 0 | |
| €31.31 | -0.453 | -1.4% | €31.34 | €31.51 | €30.81 | 300 | |
| €31.76 | +0.039 | +0.1% | €31.94 | €31.94 | €31.51 | 0 | |
| €31.72 | -0.179 | -0.6% | €32.02 | €32.12 | €31.68 | 0 | |
| €31.90 | +1.137 | +3.7% | €31.99 | €32.00 | €31.65 | 0 | |
| €30.76 | -0.744 | -2.4% | €30.78 | €31.30 | €30.70 | 0 | |
| €31.51 | -0.143 | -0.5% | €31.61 | €31.62 | €31.43 | 120 | |
| €31.65 | -0.941 | -2.9% | €31.89 | €31.90 | €31.54 | 0 | |
| €32.59 | -0.799 | -2.4% | €32.98 | €33.08 | €32.38 | 1,142 | |
| €33.39 | -1.074 | -3.1% | €33.76 | €33.99 | €33.11 | 792 | |
| €34.46 | +0.29 | +0.8% | €34.42 | €34.58 | €34.25 | 0 | |
| €34.17 | -0.151 | -0.4% | €34.20 | €34.21 | €34.03 | 12 | |
| €34.32 | +0.493 | +1.5% | €34.57 | €34.60 | €34.28 | 660 | |
| €33.83 | -1.135 | -3.2% | €33.96 | €34.04 | €33.60 | 0 | |
| €34.97 | +0.436 | +1.3% | €35.07 | €35.22 | €34.86 | 0 | |
| €34.53 | -0.624 | -1.8% | €35.03 | €35.37 | €34.14 | 240 | |
| €35.15 | -0.177 | -0.5% | €35.21 | €35.21 | €34.80 | 40 | |
| €35.33 | -0.266 | -0.7% | €35.75 | €35.80 | €35.18 | 0 | |
| €35.60 | +4.777 | +15.5% | €35.72 | €35.90 | €35.37 | 100 | |
| €30.82 | +1.379 | +4.7% | €29.70 | €30.86 | €29.50 | 860 | |
| €29.44 | +0.275 | +0.9% | €29.50 | €29.74 | €29.32 | 0 | |
| €29.17 | -0.009 | 0.0% | €29.19 | €29.19 | €29.16 | 200 | |
| €29.17 | +0.122 | +0.4% | €29.31 | €29.31 | €29.06 | 0 | |
| €29.05 | -0.252 | -0.9% | €29.30 | €29.38 | €28.97 | 0 | |
| €29.30 | -0.065 | -0.2% | €29.39 | €29.64 | €29.26 | 0 | |
| €29.37 | -2.007 | -6.4% | €29.49 | €29.49 | €29.31 | 0 | |
| €31.38 | +0.424 | +1.4% | €32.27 | €32.29 | €31.36 | 200 | |
| €30.95 | +0.144 | +0.5% | €30.99 | €30.99 | €30.93 | 0 | |
| €30.81 | +0.136 | +0.4% | €30.82 | €30.82 | €30.80 | 0 | |
| €30.67 | +0.151 | +0.5% | €30.67 | €30.67 | €30.66 | 0 | |
| €30.52 | -0.754 | -2.4% | €30.60 | €30.66 | €30.23 | 900 | |
| €31.28 | +0.129 | +0.4% | €31.21 | €31.33 | €31.21 | 314 | |
| €31.15 | -0.456 | -1.4% | €31.62 | €31.84 | €31.10 | 0 |
- Ticker
- Frankfurt:87S
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 9, 2026
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business Update
Latest earnings call · Nov 9, 2026
Roivant Sciences (NASDAQ:ROIV) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Nov 9, 2026
Q2 2026 Earnings Presentation
Earnings · 44 slides
Latest news
Priovant Announces Publication of Phase 2 BEACON Results for Brepocitinib in Cutaneous Sarcoidosis in JAMA Dermatology
Nov 10, 2026
Issued by another party
Roivant Social Ventures Announced Support of No Patient Left Behind with Six-Figure Organizational Legacy Gift
Oct 29, 2026
Closed €33.71 (+3.8%) on Oct 29, 2026
Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)
Oct 21, 2026
Closed €32.30 (+7.7%) on Oct 21, 2026
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
Oct 21, 2026
Closed €32.30 (+7.7%) on Oct 21, 2026
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Sep 23, 2026
Closed €32.59 (-2.4%) on Sep 23, 2026
Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
Sep 8, 2026
Closed €30.82 (+4.7%) on Sep 8, 2026
Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call
Sep 6, 2026
Closed €29.44 (+0.9%) on Sep 7, 2026
Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026
Sep 6, 2026
Closed €29.44 (+0.9%) on Sep 7, 2026
Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
Aug 27, 2026
Closed €31.38 (+1.4%) on Aug 28, 2026
Roivant Sciences Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 26 in the last 12 months · 115 in all · newest Nov 10, 2026 · oldest 2021
- Calls
- 21 calls with a replay · 21 with a transcript · latest Nov 9, 2026
- Decks
- 22 decks · latest Nov 9, 2026
Where Roivant Sciences Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ROIV · Home listing | NASDAQ | United States | USD |
| gettex:87S | gettex | Germany | EUR |
| LS Exchange:A3C4MS | LS Exchange | Germany | EUR |
| Tradegate:87S | Tradegate | Germany | EUR |
| BX Swiss:ROIV | BX Swiss | Switzerland | CHF |
| Lang & Schwarz:A3C4MS | Lang & Schwarz | Germany | EUR |
| BOATS:ROIV | BOATS | United States | USD |
| Dusseldorf:87S | Dusseldorf | Germany | EUR |
| Frankfurt:87S · This page | Frankfurt | Germany | EUR |
| Munich:87S | Munich | Germany | EUR |
| Stuttgart:87S | Stuttgart | Germany | EUR |
Valuation
EV/sales 580× against a median of 8.1×: the highest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $23.82B USD
- P/E
- Loss
- EV/sales
- 580×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 7.0×
- Gross margin
- 88.7%
- Operating margin
- Revenue too small
- Net margin
- −838.2%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.00
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Roivant Sciences Ltd. · NASDAQ:ROIV | US$27.92B | US$23.82B | n/a | 580× | n/a | 7.0× | −838.2% | 0.0× | 1.00 |
| CSL Limited · ASX:CSL | US$62.67B | US$72.05B | n/a | 4.6× | 14.3× | 4.2× | −16.4% | 0.7× | n/a |
| Biogen Inc. · NASDAQ:BIIB | US$36.89B | US$42.88B | 106× | 4.2× | n/a | 1.9× | 3.4% | 0.4× | 0.34 |
| Genmab A/S · OMXCOP:GMAB | US$31.30B | US$34.64B | 42.9× | 8.1× | 24.4× | 4.9× | 17.0% | 0.8× | n/a |
| Insmed Incorporated · NASDAQ:INSM | US$31.01B | US$30.41B | n/a | 20.0× | n/a | 42.7× | −39.9% | 0.8× | 0.01 |
| Alnylam Pharmaceuticals, Inc. · NASDAQ:ALNY | US$19.26B | US$15.68B | 7.3× | n/a | n/a | 5.3× | n/a | 0.0× | 0.58 |
| Ascendis Pharma A/S · NASDAQ:ASND | US$16.73B | US$16.15B | 17.1× | 12.2× | 61.1× | 10.0× | 73.5% | 0.3× | 0.49 |
| Exelixis, Inc. · NASDAQ:EXEL | US$15.77B | US$14.88B | 17.8× | 6.0× | n/a | 8.6× | 35.4% | 0.0× | 0.69 |
| Neurocrine Biosciences, Inc. · NASDAQ:NBIX | US$15.24B | US$14.50B | 21.7× | 3.9× | n/a | 3.9× | 19.0% | 0.0× | 0.79 |
| PharmaEssentia Corp. · TWSE:6446 | US$15.10B | US$14.39B | 65.3× | 22.9× | 56.4× | 13.5× | 36.8% | 0.0× | n/a |
| BridgeBio Pharma, Inc. · NASDAQ:BBIO | US$14.86B | US$15.95B | n/a | 16.9× | n/a | n/a | −59.8% | n/a | 0.89 |
| Median of the others | US$18.00B | US$16.05B | 21.7× | 8.1× | 40.4× | 5.3× | 17.0% | 0.3× | 0.58 |
Forecasts
9 strong buy · 2 buy · 2 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 50.36 USD · Analysts' mean
- EPS, year to Mar 2027
- -1.56 · 3 analysts
- Revenue, year to Mar 2027
- 51.67M · 9 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Eric Venker | Roivant President and Immunovant CEO |
| Richard Pulik | Chief Financial Officer |
| Frank Torti | Vant Chair & President |
| Mayukh Sukhatme | President & Chief Investment Officer |
| Stephanie Lee Griffin | Chief Operating Officer, Roivant Platforms |
| Sam Kaplan | General Counsel |
| Alex Gasner | EVP, Roivant Health |
| Eric Valeur | Vice President, Head of Drug Discovery |
| Iván Cornella-Taracido | Vice President of Translational Chemical Biology |
| Jason Imbriglio | Vice President, Discovery Chemistry |
| Tudor Oprea | Vice President, Translational Informatics |
| Huafeng Xu | Chief Technology Officer |
| Ian Rosenblum | Chief Information Officer |
| Jenni Humes | Chief Accounting Officer |
| Kelly Graff | Head of People |
| Vivek Ramaswamy | Founder |
Board
| Director | Role |
|---|---|
| Ilan Oren | Compensation Committee Member, Nominating, Governance Committee Member |
| James Momtazee | Nominating and Governance Committee Member |
| Keith Manchester M.D. | Audit Committee Member |
| Meghan Fitzgerald | Audit Committee Member, Nominating and Governance Committee Member |
| Melissa Epperly | Audit Committee Member |
Events
Calls
| Call | When | Status |
|---|---|---|
| Roivant Sciences (NASDAQ:ROIV) Q2 2026 Earnings Call | Mon, Nov 09, 2026 · 8:00 AM ET | Replay |
| Roivant Sciences (NASDAQ:ROIV) Q1 2026 Earnings Call | Thu, Aug 06, 2026 · 8:00 AM ET | Replay |
| Roivant Sciences (NASDAQ:ROIV) Q4 2025 Earnings Call | Wed, May 20, 2026 · 8:00 AM ET | Replay |
| Roivant Sciences (NASDAQ:ROIV) Q3 2025 Earnings Call | Fri, Feb 06, 2026 · 8:00 AM ET | Replay |
| Roivant Sciences (NASDAQ:ROIV) Q2 2025 Earnings Call | Mon, Nov 10, 2025 · 8:00 AM ET | Replay |
| Roivant Sciences (NASDAQ:ROIV) Q1 2025 Earnings Call | Mon, Aug 11, 2025 · 8:00 AM ET | Replay |
| Roivant Sciences (NASDAQ:ROIV) Q4 2024 Earnings Call | Thu, May 29, 2025 · 8:00 AM ET | Replay |
| Roivant Sciences (NASDAQ:ROIV) Q2 2024 Earnings Call | Tue, Nov 12, 2024 · 8:00 AM ET | Replay |
| Roivant Sciences (NASDAQ:ROIV) Q1 2024 Earnings Call | Thu, Aug 08, 2024 · 8:00 AM ET | Replay |
| Roivant Sciences (NASDAQ:ROIV) Q4 2023 Earnings Call | Thu, May 30, 2024 · 8:00 AM ET | Replay |
All 21 calls
| Call | When | Status |
|---|---|---|
| Roivant Sciences (NASDAQ:ROIV) Q3 2024 Earnings Call | Tue, Feb 13, 2024 · 8:00 AM ET | Replay |
| Roivant Sciences (NASDAQ:ROIV) Q3 2023 Earnings Call | Tue, Feb 13, 2024 · 8:00 AM ET | Replay |
| Roivant Sciences (NASDAQ:ROIV) Q2 2023 Earnings Call | Mon, Nov 13, 2023 · 8:00 AM ET | Replay |
| Roivant Sciences (NASDAQ:ROIV) Q1 2023 Earnings Call | Mon, Aug 14, 2023 · 8:00 AM ET | Replay |
| Roivant Sciences (NASDAQ:ROIV) Q4 2022 Earnings Call | Wed, Jun 28, 2023 · 8:00 AM ET | Replay |
| Roivant Sciences (NASDAQ:ROIV) Q3 2022 Earnings Call | Mon, Feb 13, 2023 · 8:00 AM ET | Replay |
| Roivant Sciences (NASDAQ:ROIV) Q2 2022 Earnings Call | Mon, Nov 14, 2022 · 8:00 AM ET | Replay |
| Roivant Sciences (NASDAQ:ROIV) Q1 2022 Earnings Call | Mon, Aug 15, 2022 · 8:00 AM ET | Replay |
| Roivant Sciences (NASDAQ:ROIV) Q4 2021 Earnings Call | Tue, Jun 28, 2022 · 8:00 AM ET | Replay |
| Roivant Sciences (NASDAQ:ROIV) Q3 2021 Earnings Call | Mon, Feb 14, 2022 · 8:00 AM ET | Replay |
| Roivant Sciences (NASDAQ:ROIV) Q2 2021 Earnings Call | Wed, Nov 17, 2021 · 8:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q2 2027 | Nov 9, 2026 · Before open | +4.6% |
| Q1 2027 | Aug 6, 2026 · Before open | +1.5% |
| Q4 2026 | May 20, 2026 · Before open | +14.9% |
| Q3 2026 | Feb 6, 2026 · Before open | +22.1% |
| Q2 2026 | Nov 10, 2025 · Before open | +2.7% |
| Q1 2026 | Aug 11, 2025 · Before open | −2.8% |
| Q4 2025 | May 29, 2025 | +3.5% |
| Q3 2025 | Feb 10, 2025 · Before open | −0.9% |
| Q2 2025 | Nov 12, 2024 · Before open | −1.4% |
| Q1 2025 | Aug 8, 2024 · Before open | +6.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2024 | May 30, 2024 · Before open | −3.2% |
| Q3 2024 | Feb 13, 2024 · Before open | −0.6% |
| Q2 2024 | Nov 13, 2023 · Before open | +2.7% |
| Q1 2024 | Aug 14, 2023 · Before open | +1.2% |
| Q4 2023 | Jun 28, 2023 · Before open | +11.3% |
| Q3 2023 | Feb 13, 2023 · Before open | +1.8% |
| Q2 2023 | Nov 14, 2022 · Before open | +2.5% |
| Q1 2023 | Aug 15, 2022 · Before open | −2.8% |
| Q4 2022 | Jun 28, 2022 · Before open | +0.4% |
| Q3 2022 | Feb 14, 2022 · Before open | +5.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q2 2026 Earnings Presentation | Earnings | 44 slides | Nov 9, 2026 |
| Corporate Update (August 2026) | Corporate update | 27 slides | Aug 28, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 22 slides | Aug 6, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 32 slides | Feb 6, 2026 |
| Investor Day (December 2025) | Investor day | 192 slides | Dec 11, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 31 slides | Nov 10, 2025 |
| Technical Presentation (September 2025) | Technical | 32 slides | Sep 17, 2025 |
| Technical Presentation (September 2025) | Technical | 23 slides | Sep 3, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 25 slides | Aug 11, 2025 |
| Technical Presentation (March 2025) | Technical | 36 slides | Mar 19, 2025 |
All 22 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Merger or Acquisition (September 2024) | Merger or acquisition | 8 slides | Sep 18, 2024 |
| FY2024 Earnings Presentation | Earnings | 33 slides | May 30, 2024 |
| J.P. Morgan Healthcare Conference 2024 | Conference | 21 slides | Jan 8, 2024 |
| Corporate Update (November 2023) | Corporate update | 27 slides | Nov 28, 2023 |
| Investor Presentation (November 2023) | Investor deck | 93 slides | November 2023 |
| Technical Presentation (September 2023) | Technical | 23 slides | Sep 26, 2023 |
| Technical Presentation (June 2023) | Technical | 25 slides | June 2023 |
| Investor Presentation (September 2022) | Investor deck | 21 slides | Sep 28, 2022 |
| Investor Day (March 2022) | Investor day | 86 slides | Mar 30, 2022 |
| Investor Day (September 2021) | Investor day | 131 slides | Sep 28, 2021 |
| SPAC Merger (June 2021) | SPAC merger | 114 slides | Jun 25, 2021 |
| SPAC Merger (May 2021) | SPAC merger | 95 slides | May 3, 2021 |
Financials
Annual, in USD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.26M | 29.1M | 32.7M | 31.5M | 55.3M | 23.8M | 67.7M | 2.32M |
| Cost of revenue | 1.28M | 911.0K | 1.60M | 3.03M | 8.97M | 2.06M | 1.13M | 606.0K |
| Gross profit | 6.97M | 28.1M | 31.1M | 28.5M | 46.3M | 21.7M | 66.6M | 1.72M |
| Research and development | 681.8M | 550.4M | 439.9M | 454.1M | 483.0M | 236.6M | 263.2M | 513.0M |
| Selling, general and administrative | 610.5M | 591.4M | 687.4M | 600.5M | 775.0M | 259.9M | 335.8M | 237.2M |
| Operating income | -515.1M | -1.00B | 4.50B | -906.8M | -1.35B | -1.07B | -532.4M | -748.5M |
| Depreciation and amortization | 3.35M | 14.1M | 22.0M | 18.9M | 5.93M | 5.93M | 5.93M | 748.5M |
| EBITDA | -511.7M | -989.2M | 4.52B | -887.9M | -1.35B | -1.06B | -526.5M | 0 |
| Interest expense | 34.8M | 28.0M | 7.04M | 2.81M | 7.68M | 7.54M | ||
| Income before tax | -264.6M | -681.6M | 4.57B | -885.0M | -923.7M | -898.5M | -561.0M | -807.2M |
| Income tax | 133.3M | 48.2M | 21.5M | 4.08M | 369.0K | 1.69M | 7.12M | 2.62M |
| Net income | -299.8M | -172.0M | 4.35B | -1.01B | -845.3M | -809.2M | 1.20B | -1.04B |
| Earnings per share, basic | -0.43 | -0.24 | 5.55 | -1.42 | -1.26 | -1.28 | 1.75 | -4.84 |
| Earnings per share, diluted | -0.54 | -0.24 | 5.23 | -1.42 | -1.26 | -1.28 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.42B | 2.72B | 6.49B | 1.68B | 2.06B | 2.06B | 2.19B | 849.6M |
| Short-term investments | 2.87B | 2.17B | 0 | 5.01M | 13.6M | 77.7M | ||
| Receivables | 789.8M | 3.99M | 30.4M | 3.88M | 11.2M | 15.3M | 11.0M | |
| Inventory | 35.3M | 2.76M | 0 | 63.9M | 1 | |||
| Current assets | 5.17B | 5.00B | 6.73B | 1.80B | 2.15B | 2.19B | 2.22B | 1.19B |
| Property, plant and equipment | 12.0M | 12.1M | 15.3M | 39.1M | 25.9M | 14.7M | 73.9M | 11.1M |
| Total assets | 5.71B | 5.44B | 7.22B | 2.39B | 2.59B | 2.59B | 2.48B | 1.39B |
| Accounts payable | 18.0M | 23.7M | 14.0M | 37.8M | 34.6M | 20.6M | 10.3M | 6.23M |
| Current liabilities | 281.2M | 149.4M | 266.8M | 272.4M | 184.4M | 219.0M | 92.1M | 211.3M |
| Long-term debt | 430.6M | 375.5M | 210.0M | 170.3M | ||||
| Total debt | 107.4M | 100.2M | 430.6M | 375.5M | 210.0M | 170.3M | 180.9M | 143.2M |
| Total liabilities | 416.3M | 249.7M | 774.0M | 782.0M | 523.7M | 527.7M | 368.4M | 450.5M |
| Shareholders' equity | 4.53B | 4.69B | 5.97B | 1.16B | 1.66B | 1.80B | 2.03B | 937.3M |
| Shares outstanding | 720.4M | 695.9M | 806.7M | 760.1M | 695.0M | 651.6M | 684.8M | 215.4M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -750.3M | -839.5M | -765.3M | -843.4M | -677.7M | -552.1M | -761.8M | -1.02B |
| Capital spending | -8.21M | -4.60M | -1.38M | -12.7M | -17.4M | -5.81M | -4.92M | -11.4M |
| Free cash flow | -758.6M | -844.0M | -766.6M | -856.1M | -695.2M | -557.9M | -766.7M | -1.04B |
| Cash from investing | -682.3M | -1.77B | 5.20B | -44.3M | 303.3M | -31.7M | 1.69B | -57.6M |
| Cash from financing | 134.2M | -1.22B | 419.4M | 499.5M | 306.8M | 456.3M | 217.2M | 767.0M |
| Dividends paid | -6.00M | -162.7M | ||||||
| Share buybacks | -319.5M | -1.29B | 0 | 0 | -113.0K | -1.19B | -7.38M | |
| Change in cash | -1.29B | -3.82B | 4.86B | -381.9M | -67.6M | -127.6M | 1.34B | 1.12B |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 3 · Initial statement of ownership | Nov 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 144/A · Notice of proposed sale, amended | Nov 13, 2026 | Other filings | SEC |
| 144/A · Notice of proposed sale, amended | Nov 13, 2026 | Other filings | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 12, 2026 | Other filings | SEC |
| 144/A · Notice of proposed sale, amended | Nov 10, 2026 | Other filings | SEC |
| 144/A · Notice of proposed sale, amended | Nov 10, 2026 | Other filings | SEC |
| 144/A · Notice of proposed sale, amended | Nov 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 10, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 9, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2026 | Results | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Nov 3, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 30, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 28, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 27, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 22, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 21, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 20, 2026 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 30, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 18, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Sep 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 8, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 8, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 28, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 28, 2026 | Current report | SEC |
| 8-K · Current report | Aug 27, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 21, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 20, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 19, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 14, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 29, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Jul 29, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Jul 29, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jul 29, 2026 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Jul 27, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 30, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 30, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 29, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 26, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 25, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 24, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 22, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | May 20, 2026 | Offer document | SEC |
| 10-K · Annual report | May 20, 2026 | Annual report | SEC |
| 8-K · Current report | May 20, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 20, 2026 | Other filings | SEC |
| 144/A · Notice of proposed sale, amended | Apr 16, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 16, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 10, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 8, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 2, 2026 | Results | SEC |
| 4 · Change in ownership | Apr 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 30, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Mar 26, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 24, 2026 | Insider trade | SEC |
| 8-K/A · Current report, amended | Mar 23, 2026 | Material contract | SEC |
| 4 · Change in ownership | Mar 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 16, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 6, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 3, 2026 | Material contract | SEC |
| 8-K · Current report | Mar 3, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 20, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 19, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 13, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 11, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Feb 9, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Feb 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Feb 6, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 12, 2026 | Other filings | SEC |
| 4 · Change in ownership | Dec 31, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 31, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 29, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 29, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 29, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 23, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 23, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 23, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 17, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 144/A · Notice of proposed sale, amended | Dec 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 15, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 11, 2025 | Current report | SEC |
| 144 · Notice of proposed sale | Dec 9, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from Roivant Sciences Ltd.’s releases
- Common shares
- 722,323,015
- Fully diluted
- 722,323,015
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 722,323,015 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 722,323,015 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Eric Venker Other companies: Immunovant, Inc. (Chief Executive Officer · Since at least Feb 18, 2020); Arbutus Biopharma Corporation (Director · Feb 18, 2020 – Feb 18, 2020 · Past); Sio Gene Therapies Inc (Director · Feb 17, 2020 – Feb 17, 2020 · Past) | Roivant President and Immunovant CEO · Since at least Oct 1, 2021 |
| Andrew Lo Other companies: AbCellera Biologics Inc. (Director · Since at least Dec 3, 2021); BridgeBio Pharma, Inc. (Director · Since at least Jun 23, 2020) | Director · Oct 1, 2021 – Sep 15, 2022 · Past |
| James Momtazee Other companies: BridgeBio Pharma, Inc. (Director · Since at least Jun 27, 2019); PRA Health Sciences Inc (Director · Aug 13, 2019 – Jul 1, 2021 · Past) | Nominating and Governance Committee Member · Since at least Oct 1, 2021 |
| Rakhi Kumar Other companies: Amanat Acquisition Corp (Director · Since at least May 18, 2026); NeuroPace, Inc. (Director · Since at least Jun 7, 2024) | Chief Accounting Officer · Oct 24, 2023 – Feb 20, 2025 · Past |
| Frank Torti Other companies: Immunovant, Inc. (Director · Since at least Apr 1, 2025) | President and Vant Chair · Since at least Jul 29, 2025 |
| Frank Torti Other companies: Immunovant, Inc. (Executive Chairman · Since at least Apr 9, 2026) | Vant Chair & President · Since at least May 20, 2026 |
| Matthew Gline Other companies: Arbutus Biopharma Corporation (Director · Since at least Feb 24, 2025) | CEO, Director · Since at least Oct 1, 2021 |
| Meghan Fitzgerald Other companies: Tenet Healthcare Corporation (Director · Since at least May 7, 2021) | Audit Committee Member, Nominating and Governance Committee Member · Since at least Mar 13, 2023 |
| Alex Gasner | EVP, Roivant Health · Since at least Nov 4, 2026 |
| Eric Valeur | Vice President, Head of Drug Discovery · Since at least Nov 4, 2026 |
All 27 people
| Person | Seat |
|---|---|
| Huafeng Xu | Chief Technology Officer · Since at least Nov 4, 2026 |
| Ian Rosenblum | Chief Information Officer · Since at least Nov 4, 2026 |
| Ilan Oren | Compensation Committee Member, Nominating, Governance Committee Member · Since at least Apr 17, 2026 |
| Iván Cornella-Taracido | Vice President of Translational Chemical Biology · Since at least Nov 4, 2026 |
| Jason Imbriglio | Vice President, Discovery Chemistry · Since at least Nov 4, 2026 |
| Jennifer Humes | Chief Accounting Officer · Since at least Feb 19, 2025 |
| Jenni Humes | Chief Accounting Officer · Since at least Sep 22, 2026 |
| Keith Manchester M.D. | Audit Committee Member · Since at least Jun 25, 2025 |
| Kelly Graff | Head of People · Since at least Nov 4, 2026 |
| Matt Gline | Aug 27, 2026 – Oct 30, 2026 · Past |
| Mayukh Sukhatme | President & Chief Investment Officer · Since at least Dec 17, 2025 |
| Melissa Epperly | Audit Committee Member · Since at least Oct 27, 2026 |
| Richard Pulik | Chief Financial Officer · Since at least Mar 28, 2025 |
| Sam Kaplan | General Counsel · Since at least Nov 4, 2026 |
| Stephanie Lee Griffin | Chief Operating Officer, Roivant Platforms · Since at least Nov 5, 2026 |
| Tudor Oprea | Vice President, Translational Informatics · Since at least Nov 4, 2026 |
| Vivek Ramaswamy | Founder · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Roivant Sciences Ltd.